ARTICLE | Company News
ImmunoGen and Genentech in cancer deal
May 4, 2000 7:00 AM UTC
DNA received a global exclusive license to use IMGN's maytansinoid Tumor-Activated Prodrug (TAP) technology to develop and commercialize products targeting HER2. IMGN will receive a $2 million up-fron...